Science Times: Comprehensive Genomic Analysis of Infiltrative Gliomas Based on Molecular Profile

Diffusely infiltrating gliomas make up a heterogeneous cohort of tumors with variable prognosis and response to treatment. Survival can range from <1 to >15 years. Approximately two-thirds of World Health Organization (WHO) grade II gliomas undergo pathological progression to anaplastic astrocytomas or glioblastoma multiforme (GBM).1 Management of lower-grade diffuse gliomas is particularly challenging because histopathological distinction may be limited by significant interobserver variability and because tumor growth or transformation may occur at unpredictable time points.2

Full text access is available to all readers.